Drug Trial Radar · NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 3, 2023
Primary completion
Feb 22, 2032
Study completion Feb 22, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of nonserious adverse events (AEs) leading to permanent discontinuationTime frame: A minimum of 90 days after the last dose of study drug
- Incidence of serious adverse events (SAEs)Time frame: A minimum of 90 days after the last dose of study drug
Locations
33 sites in 7 countries. Site status is shown where the registry gives one.
UCI Health - Irvine Infusion Pharmacy ACC
Irvine, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
UCI Health
Orange, California · Recruiting
UCHealth Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
UCHealth Harmony
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Longs Peak Hospital
Longmont, Colorado · Recruiting
UCHealth Longs Peak Medical Center
Longmont, Colorado · Recruiting
UCHealth - Medical Center of the Rockies
Loveland, Colorado · Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida · Recruiting
University of Miami Hospital and Clinics Deerfield Beach
Deerfield Beach, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Miami Hospital and Clinics - Griffin Cancer Research Building
Miami, Florida · Recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan · Recruiting
St. David's South Austin Medical Center
Austin, Texas · Recruiting
Epworth Freemasons
Melbourne, Victoria, Australia · Recruiting
Epworth Hospital
Richmond, Victoria, Australia · Recruiting
Slade Pharmacy
Richmond, Victoria, Australia · Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Active not recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Active not recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Recruiting
The first Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, Japan · Recruiting
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, Japan · Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Hospital Universitario Doctor Peset
Valencia, València, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.